This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Codexis Celebrates 10 Years Of Technical And Commercial Success

Codexis, Inc. (Nasdaq:CDXS), a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, tomorrow will celebrate 10 years as a company. Since its founding in 2002, the company has developed, improved and applied its CodeEvolver™ Directed Evolution platform across a broad spectrum of industries. Codexis technology has enabled significant improvements in manufacturing processes for pharmaceutical intermediates for some of the world’s largest blockbuster drugs, and has created customized advanced enzymes and organisms for use in industrial biofuels, renewable chemicals, and carbon capture applications.

“We have accomplished a tremendous amount in the past 10 years, including achieving key breakthroughs in our directed evolution technology, delivering products to a wide array of pharmaceutical clients, and establishing a successful partnership with Shell leading to major advancements in our biofuels technology,” said Peter Strumph, Interim Chief Executive Officer. “In the next 10 years, we believe our technology leaves us well positioned to continue to grow our pharmaceuticals business and be a significant player in the emerging renewable fuels and chemicals fields. Our success, past and future, can be credited to our dedicated team of employees in the U.S., Europe and Asia. Their ability to innovate and consistently deliver results is unsurpassed.”

At a 10 th anniversary event at Codexis headquarters in Redwood City, employees and distinguished guests will celebrate the company’s achievements, and management will lay out a vision for the next 10 years. Some of the specific accomplishments and awards Codexis has achieved include:

  • Two EPA Presidential Green Chemistry Awards for clean manufacturing processes for market-leading therapeutics for diabetes and heart disease
  • Draper Prize from National Academy of Engineering (NAE) to developers of Codexis core platform technology in directed evolution
  • Establishment of research centers of excellence in Singapore and Budapest
  • Completion of the first advanced biofuels company IPO in 2010
  • Longstanding collaborative partnerships with global leaders including Shell, Merck, Pfizer and Chemtex

About Codexis, Inc.

Codexis, Inc. is a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates. Codexis’ product lines include CodeXyme™ Cellulase Enzymes and CodeXol™ Detergent Alcohol. Partners and customers include global leaders such as Shell, Merck and Pfizer. For more information, see

Forward-Looking Statements

This press release contains forward-looking statements relating to the Codexis business strategy referred to in this press release. (Legal to update language) Additional factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2012, including under the caption “Risk Factors.” Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs